The introduction of lanreotide, in the form of Somatuline Autogel ® (SCRAS, Paris, France)—which does not require reconstitution before injection and is available in ready-to-use, prefilled ...

or to the combination of everolimus (10 mg/d) and lanreotide (120 mg every 28 days). Median progression-free survival (the primary outcome) was 29.7 months in the everolimus plus lanreotide group ...